Market Trends of Shingles Vaccine Industry
Shingrix is Expected to have Significant Growth in the Market Over the Forecast Period
Shingrix is an adjuvanted subunit vaccine that contains recombinant VZV glycoprotein E (gE). It is used in adults aged 50 years and over to protect against shingles (herpes zoster) and post-herpetic neuralgia (long-lasting nerve pain following shingles). The Shingrix is anticipated to hold the major share in the market attributable to the high efficacy of these vaccines with fewer consequences associated with them. Furthermore, the increase in awareness regarding the consequences of the disease and an increasing number of regulatory approval for Shingrix in various countries are contributing to an increase in demand for these vaccines during the forecast period.
Moreover, the high adoption of Shingrix among the developed countries in the North American and the European region also helps to boost the demand for these vaccines. After being licensed in the United Kingdom in September 2021, this vaccine was included in the national shingles immunization program.
In addition, the new approvals and launches of this vaccine in various regions increase the widespread distribution of Shingrix. For instance, in June 2022, Japan's MHLW accepted Shingrix's regulatory submission to prevent shingles in at-risk adults aged 18 years and older. Similarly, in January 2022, GSK launched Shingrix in Singapore for the prevention of shingles across the country. Thus, the new initiatives by the market players through new approvals and launches increase the widespread distribution of the vaccine and are expected to boost the market over the forecast period.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to hold a significant share in the shingles vaccines market throughout the forecast period. The government's recommendation of the use of shingles vaccines, the presence of sophisticated healthcare infrastructure, and high awareness among patients regarding the importance of these vaccines are some prominent drivers for the growth of the shingles vaccine market during the forecast period.
Since shingles are caused due to the reactivation of the chickenpox virus, the high prevalence of chickenpox is expected to boost the requirement for shingles vaccines. For instance, in September 2022, Mexican health authorities reported 21,060 infections of chickenpox 2022 (11,057 men and 10,003 women), a much higher figure than in 2021, when 8,897 infections were registered, representing an increase of 137%. The high incidence rate of chickenpox increases the risk of the occurrence of shingles.
Furthermore, the availability of shingles vaccines for immunocompromised adults is expected to boost market growth. For instance, in October 2021, the CDC panel voted to recommend Shingrix as a vaccine against shingles for immunodeficient or immunosuppressed adults. Similarly, in July 2021, GSK plc received approval from United States FDA for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. These factors contribute to the high demand for shingles vaccines in the North American region and are expected to have a significant impact on the market over the forecast period.
